Atenativ is a medication used in this clinical trial to help patients who have a condition called congenital antithrombin deficiency. This condition means that their blood does not have enough of a protein called antithrombin, which helps prevent blood clots. When people with this deficiency undergo surgery or give birth, they are at a higher risk of developing blood clots. Atenativ is given to these patients to increase the levels of antithrombin in their blood, which helps reduce the risk of blood clots forming during these procedures. The trial is studying how well Atenativ works in preventing these clotting events and ensuring it is safe for the patients to use.

Congenital antithrombin deficiency – Congenital antithrombin deficiency is a genetic disorder characterized by a reduced level of antithrombin, a protein that helps regulate blood clotting. This deficiency leads to an increased risk of developing abnormal blood clots, known as thrombotic events, which can occur in veins or arteries. The condition is present from birth and can vary in severity among individuals. As the deficiency progresses, individuals may experience recurrent clotting episodes, especially during situations that increase clotting risk, such as surgery or childbirth. The disorder is typically inherited in an autosomal dominant pattern, meaning one copy of the altered gene in each cell is sufficient to cause the condition. Over time, the risk of clot formation can lead to complications if not managed properly.